[Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus].

Q3 Medicine
北京大学学报(医学版) Pub Date : 2024-12-18
Shuai Liu, Lei Liu, Zhuo Liu, Fan Zhang, Lulin Ma, Xiaojun Tian, Xiaofei Hou, Guoliang Wang, Lei Zhao, Shudong Zhang
{"title":"[Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus].","authors":"Shuai Liu, Lei Liu, Zhuo Liu, Fan Zhang, Lulin Ma, Xiaojun Tian, Xiaofei Hou, Guoliang Wang, Lei Zhao, Shudong Zhang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinicopathological features, prognostic value and surgical treatment experience in patients with adrenocortical carcinoma with venous tumor thrombus.</p><p><strong>Methods: </strong>We collected relevant data of the patients with adrenocortical carcinoma who had undergone surgery in Peking University Third Hospital from 2018 to 2023. The patients were divided into venous tumor thrombus group and non-tumor thrombus group. The Wilcoxon rank sum test was used to compare the quantitative variables. The chi-squared test and Fisher's exact test were used to compare the categorical variables. The Kaplan-Meier method was used to estimate the survival rate.</p><p><strong>Results: </strong>A total of 27 patients with adrenocortical carcinoma were included, of whom 11 cases (40.7%) had venous tumor thrombus. In the patients with venous tumor thrombus, 8 patients were female and 3 were male. The median age was 49 (36, 58) years. The median body mass index was 26.0 (24.1, 30.4) kg/m<sup>2</sup>. Seven patients presented with symptoms at their initial visit. Six patients had a history of hypertension. Elevated levels of cortisol were observed in 2 cases. Three tumors were found on the left side, while 8 were found on the right side. Median tumor diameter was 9.4 (6.5, 12.5) cm. On the left, there was a case of tumor thrombus limited to the central vein of the left adrenal gland without invasion into the left renal vein, and two cases of tumor thrombus growth extending into the inferior vena cava below the liver. One case of tumor thrombus on the right adrenal central vein did not invade the inferior vena cava. Four cases of tumor thrombus invaded the inferior vena cava below the liver and three cases extended to the posterior of the liver. Ten patients were in European Network for the Study of Adrenal Tumors (ENSAT) stage Ⅲ and one was in ENSAT stage Ⅳ. Open surgery was performed in 6 cases, laparoscopic surgery alone in 4 cases and robot-assisted laparoscopic surgery in 1 case. Two patients underwent ipsilateral kidney resection. Median operative time was 332 (261, 440) min. Median intraoperative bleeding was 900 (700, 2 200) mL. Median hospital stay was 9 (5, 10) days. Median survival time for the patients with tumor thrombus was 24.0 months and median time to recurrence was 7.0 months. The median survival and recurrence time of 16 patients without tumor thrombus were not reached. The patients with tumor thrombus had worse 3-year overall survival (OS) rate (40.9% <i>vs</i>. 71.4%; Log-rank, <i>P</i>=0.038) and 2-year recurrence-free survival (RFS) (9.1% <i>vs</i>.53.7%; Log-rank, <i>P</i>=0.015) rates compared with the patients with non-tumor thrombus.</p><p><strong>Conclusion: </strong>Patients with adrenocortical carcinoma with venous tumor thrombus have poor prognosis. Different adrenal tumor resections and venous tumor thrombus removal procedures based on different tumor thrombus locations are safe and effective in treating this disease.</p>","PeriodicalId":8790,"journal":{"name":"北京大学学报(医学版)","volume":"56 4","pages":"624-630"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284474/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"北京大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To analyze the clinicopathological features, prognostic value and surgical treatment experience in patients with adrenocortical carcinoma with venous tumor thrombus.

Methods: We collected relevant data of the patients with adrenocortical carcinoma who had undergone surgery in Peking University Third Hospital from 2018 to 2023. The patients were divided into venous tumor thrombus group and non-tumor thrombus group. The Wilcoxon rank sum test was used to compare the quantitative variables. The chi-squared test and Fisher's exact test were used to compare the categorical variables. The Kaplan-Meier method was used to estimate the survival rate.

Results: A total of 27 patients with adrenocortical carcinoma were included, of whom 11 cases (40.7%) had venous tumor thrombus. In the patients with venous tumor thrombus, 8 patients were female and 3 were male. The median age was 49 (36, 58) years. The median body mass index was 26.0 (24.1, 30.4) kg/m2. Seven patients presented with symptoms at their initial visit. Six patients had a history of hypertension. Elevated levels of cortisol were observed in 2 cases. Three tumors were found on the left side, while 8 were found on the right side. Median tumor diameter was 9.4 (6.5, 12.5) cm. On the left, there was a case of tumor thrombus limited to the central vein of the left adrenal gland without invasion into the left renal vein, and two cases of tumor thrombus growth extending into the inferior vena cava below the liver. One case of tumor thrombus on the right adrenal central vein did not invade the inferior vena cava. Four cases of tumor thrombus invaded the inferior vena cava below the liver and three cases extended to the posterior of the liver. Ten patients were in European Network for the Study of Adrenal Tumors (ENSAT) stage Ⅲ and one was in ENSAT stage Ⅳ. Open surgery was performed in 6 cases, laparoscopic surgery alone in 4 cases and robot-assisted laparoscopic surgery in 1 case. Two patients underwent ipsilateral kidney resection. Median operative time was 332 (261, 440) min. Median intraoperative bleeding was 900 (700, 2 200) mL. Median hospital stay was 9 (5, 10) days. Median survival time for the patients with tumor thrombus was 24.0 months and median time to recurrence was 7.0 months. The median survival and recurrence time of 16 patients without tumor thrombus were not reached. The patients with tumor thrombus had worse 3-year overall survival (OS) rate (40.9% vs. 71.4%; Log-rank, P=0.038) and 2-year recurrence-free survival (RFS) (9.1% vs.53.7%; Log-rank, P=0.015) rates compared with the patients with non-tumor thrombus.

Conclusion: Patients with adrenocortical carcinoma with venous tumor thrombus have poor prognosis. Different adrenal tumor resections and venous tumor thrombus removal procedures based on different tumor thrombus locations are safe and effective in treating this disease.

[肾上腺皮质癌伴有静脉瘤栓的临床治疗和预后]。
目的分析肾上腺皮质癌合并静脉瘤栓患者的临床病理特征、预后价值及手术治疗经验:收集2018年至2023年在北京大学第三医院接受手术治疗的肾上腺皮质癌患者的相关资料。将患者分为静脉瘤栓组和非瘤栓组。定量变量比较采用 Wilcoxon 秩和检验。对分类变量的比较采用卡方检验和费雪精确检验。采用 Kaplan-Meier 法估计存活率:结果:共纳入27例肾上腺皮质癌患者,其中11例(40.7%)有静脉瘤栓。在有静脉瘤栓的患者中,8 例为女性,3 例为男性。年龄中位数为 49(36,58)岁。体重指数中位数为 26.0 (24.1, 30.4) kg/m2。7 名患者在初诊时出现症状。六名患者有高血压病史。2例患者皮质醇水平升高。3例肿瘤位于左侧,8例位于右侧。肿瘤直径中位数为 9.4(6.5,12.5)厘米。左侧有一例肿瘤血栓局限于左肾上腺中央静脉,未侵犯左肾静脉,有两例肿瘤血栓生长延伸至肝脏下方的下腔静脉。1例右侧肾上腺中央静脉上的肿瘤血栓没有侵入下腔静脉。4例肿瘤血栓侵入肝脏下方的下腔静脉,3例延伸至肝脏后部。10例患者为欧洲肾上腺肿瘤研究网络(ENSAT)Ⅲ期,1例为ENSATⅣ期。6例患者接受了开腹手术,4例患者接受了单纯腹腔镜手术,1例患者接受了机器人辅助腹腔镜手术。两名患者接受了同侧肾脏切除术。中位手术时间为332(261,440)分钟。术中出血量中位数为900(700,2 200)毫升。中位住院时间为9(5,10)天。肿瘤血栓患者的中位生存时间为24.0个月,中位复发时间为7.0个月。16名无肿瘤血栓患者的中位生存时间和复发时间均未达到要求。与无瘤栓患者相比,有瘤栓患者的3年总生存率(OS)(40.9% vs. 71.4%;Log-rank,P=0.038)和2年无复发生存率(RFS)(9.1% vs. 53.7%;Log-rank,P=0.015)更差:结论:伴有静脉瘤栓的肾上腺皮质癌患者预后较差。结论:肾上腺皮质癌伴有静脉瘤栓的患者预后较差,根据不同的瘤栓位置采取不同的肾上腺肿瘤切除术和静脉瘤栓清除术治疗该病安全有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
北京大学学报(医学版)
北京大学学报(医学版) Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
9815
期刊介绍: Beijing Da Xue Xue Bao Yi Xue Ban / Journal of Peking University (Health Sciences), established in 1959, is a national academic journal sponsored by Peking University, and its former name is Journal of Beijing Medical University. The coverage of the Journal includes basic medical sciences, clinical medicine, oral medicine, surgery, public health and epidemiology, pharmacology and pharmacy. Over the last few years, the Journal has published articles and reports covering major topics in the different special issues (e.g. research on disease genome, theory of drug withdrawal, mechanism and prevention of cardiovascular and cerebrovascular diseases, stomatology, orthopaedic, public health, urology and reproductive medicine). All the topics involve latest advances in medical sciences, hot topics in specific specialties, and prevention and treatment of major diseases. The Journal has been indexed and abstracted by PubMed Central (PMC), MEDLINE/PubMed, EBSCO, Embase, Scopus, Chemical Abstracts (CA), Western Pacific Region Index Medicus (WPR), JSTChina, and almost all the Chinese sciences and technical index systems, including Chinese Science and Technology Paper Citation Database (CSTPCD), Chinese Science Citation Database (CSCD), China BioMedical Bibliographic Database (CBM), CMCI, Chinese Biological Abstracts, China National Academic Magazine Data-Base (CNKI), Wanfang Data (ChinaInfo), etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信